{"id":"NCT03930615","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)","officialTitle":"A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-21","primaryCompletion":"2021-10-27","completion":"2022-03-16","firstPosted":"2019-04-29","resultsPosted":"2022-11-01","lastUpdate":"2024-08-22"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Cytomegalovirus Infection"],"interventions":[{"type":"DRUG","name":"Letermovir","otherNames":["PREVYMISâ„¢, MK-8228"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Letermovir","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants who received an allogenic hematopoietic stem cell transplant (HSCT). It was hypothesized that LET is superior to placebo in the prevention of clinically-significant CMV infection when LET prophylaxis is extended from 100 to 200 days.","primaryOutcome":{"measure":"Percentage of Participants With Clinically Significant CMV Infection From Week 14 (~100 Days) Post-transplant Through Week 28 (~200 Days) Post-transplant","timeFrame":"From Week 14 post-transplant to Week 28 post-transplant (approximately 14 weeks)","effectByArm":[{"arm":"Letermovir","deltaMin":2.8,"sd":null},{"arm":"Placebo","deltaMin":18.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":18},"locations":{"siteCount":32,"countries":["United States","France","Germany","Italy","Japan","United Kingdom"]},"refs":{"pmids":["38142695","36464218"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":144},"commonTop":["Graft versus host disease","Nausea","Diarrhoea","Oedema peripheral","Pyrexia"]}}